Jeff Jonas, portfolio manager at Gabelli Funds, said he’s “cautious” on whether J&J’s purchase of Intra-Cellular Therapies will clear regulatory hurdles.
Jeff Jonas, portfolio manager at Gabelli Funds, said he’s “cautious” on whether J&J’s purchase of Intra-Cellular Therapies will clear regulatory hurdles.
